Main Session
Sep
30
SH 09 - Lung Cancer/Thoracic Malignancies - Science Highlights
9 - Six-Year Overall Survival of Nivolumab Following Stereotactic Ablative Radiotherapy in Early-Stage Non-Small Cell Lung Cancer: Randomized I-SABR Trial
Presenter(s)
Joe Chang, MD, PhD, MS, FASTRO - MD Anderson Cancer Center, Houston, TX